Analysis of the effect of different drug regimens on blood lipids in AIDS patients based on real world data
Objective:To analyze the effect of different drug regimens on blood lipids in AIDS patients based on real world data.Methods:Based on real world data in the Hospital Information System(HIS),16 Grade Ⅲ and Class A hospitals in the province were selected by stratified random sampling method,and the medical records of 702 AIDS patients using different medication regimentation in the above hospitals were collected from January 2022 to July 2022.According to the medication regimen,they were divided into regimen 1 group[Lamivudine(3TC)+Zidovudine(AZT)+Efavirenz(EFV)],regimen 2 group[3TC+AZT+Nellavepin(NVP)],regimen 3 group[3TC+Tenofovir fumarate(TDF)+EFV]and regimen 4 group(3 TC+TDF+NVP).The fasting blood lipid levels[total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)and high density lip-oprotein cholesterol(HDL-C)]and dyslipidemia rate in each group of patients were compared before treatment and 6 months after treatment.Adverse events caused by changes in blood lipids were compared between each group of patients during the medication period.Results:After treatment,the levels of TC,TG,LDL-C and dyslipidemia rate in each group of patients were higher than that before treatment,while the level of HDL-C was lower than that before treatment,and the levels of TC,TG,LDL-C and dyslipidemia rate in the in regimen 3 and regimen 4 groups were lower than those in the regimen 1 and regimen 2 groups,respectively,while the level of HDL-C was higher than that in the regimen 1 and regimen 2 groups respectively(all P＜0.05).The incidences of adverse events caused by dyslipidemia in regimen 3 group and regimen 4 group were lower than those in regimen 1 group and regi-men 2 group,respectively(all P＜0.05).Conclusion:Compared with 3TC+AZT+EFV and 3TC+AZT+NVP treatment regimens,the treatment regimens of 3TC+TDF+EFV and 3TC+TDF+NVP can reduce the levels of TC,TG and LDL-C,increase the level of HDL-C,improve dyslipidemia and reduce the incidence of adverse events caused by dyslipidemia in AIDS patients.
real world datatenofovir disoproxil fumarateacquired immune deficiency syndromeblood lipids
NETL
NSTL
万方数据
